Conference Track

Early Breast Cancer: Endocrine Therapy

Source: CCO Independent Conference Coverage of the CCO Independent Conference Coverage of the 2007 San Antonio Breast Cancer Symposium*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

Denosumab Increases Bone Mineral Density in Postmenopausal Women Receiving AI Therapy for Nonmetastatic Breast Cancer
Switching Hormonal Therapy Likely to Improve Joint Symptoms in Postmenopausal Women
Addition of Everolimus to Letrozole Increases Response Rates in Postmenopausal Women With Newly Diagnosed, ER-Positive Breast Cancer
Risedronate Safe and Effective in Preventing Bone Loss in High-Risk Postmenopausal Women on Anastrozole for the Prevention of Breast Cancer
CYP2D6*2A Polymorphism Associated With Increased Response to Tamoxifen and Decreased Incidence of Breast Cancer
Increased Clinical Biomarker Response Demonstrated With High-Dose Fulvestrant as Neoadjuvant Treatment in Patients With ER-Positive, Locally Advanced Breast Cancer
Upfront Zoledronic Acid Associated With Decreased Bone Loss in Patients With Breast Cancer on Adjuvant Letrozole
Continuing Adjuvant Tamoxifen Beyond 5 Years May Reduce Risk of Breast Cancer Recurrence
Aromatase Inhibitor Anastrozole Associated With Increased Joint Toxicity Compared With Tamoxifen
Anastrozole Superior to Tamoxifen as Initial Adjuvant Therapy in Postmenopausal Women With Hormone-Sensitive, Early-Stage Breast Cancer
Increased CYP2D6 Activity May Predict Adherence to Tamoxifen Therapy in Women With Breast Cancer

Expert Analysis

Endocrine Therapy

Faculty:

Harold J. Burstein, MD, PhD
Peter Ravdin, MD, PhD
Eric P. Winer, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

Explain the current use of tamoxifen in patients with breast cancer
Describe the advantages of selective estrogen receptor modulators vs aromatase inhibitors in the treatment of invasive breast cancer
Discuss the use of hormone therapies to treat patients with breast cancer
Identify solutions to mitigate bone loss in patients receiving endocrine therapy for breast cancer

CME CREDIT INFORMATION

Release Date: 02/28/08

Expiration Date: 02/27/09

Physicians: maximum of 1.25 AMA PRA Category 1 Credits™

Registered Nurses: 1.3 Nursing CE credits

Pharmacists: 1.3 contact hours (0.13 CEUs)

Status: Please log in to view status

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.